Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an allogeneic hematopoietic stem cell transplant (HSCT) is proof of concept for the application of immunotherapy in AML and MDS. However, outside of HSCT, only the anti-CD33 antibody drug conjugate gemtuzumab ozogamicin is currently approved as an antibody-targeted therapy for AML. Several avenues of immunotherapeutic drugs are currently in different stages of clinical development.
Source: Blood Reviews - Category: Hematology Authors: Yuxin Liu, Jan Philipp Bewersdorf, Maximilian Stahl, Amer M. Zeidan Tags: Review Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Hematology | Immunotherapy | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants